Curated News: NEJM

Filters close
Newswise: Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response
Released: 29-May-2020 10:30 AM EDT
Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response
University of Texas M. D. Anderson Cancer Center

Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9556 – Poster 322) by researchers from The University of Texas MD Anderson Cancer Center.

Released: 28-May-2020 9:40 AM EDT
As hospitals walk the tightrope of patient data-sharing, one system offers a new balance
Michigan Medicine - University of Michigan

Every major medical center in America sits on a gold mine of patient data that could be worth millions of dollars to companies that could use it to develop new treatments and technologies. A new framework could help them do so more responsibly, going beyond the minimum legal requirements and respecting patients by giving them more say in how their individual data may be used.

Newswise: 232760_web.jpg
Released: 26-May-2020 3:15 PM EDT
Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery
NIH, National Institute of Allergy and Infectious Diseases (NIAID)

The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a report published today in The New England Journal of Medicine.

Newswise: When seizures don't stop: What's the latest in treating status epilepticus?
Released: 26-May-2020 2:50 PM EDT
When seizures don't stop: What's the latest in treating status epilepticus?
International League Against Epilepsy

When seizures last longer than about 5 minutes--a condition called status epilepticus--emergency treatment is required. About two-thirds of people respond to initial treatment with benzodiazepines, but the others need a second drug. Which drug to choose is a matter of some debate.

Released: 26-May-2020 11:35 AM EDT
Montefiore and Einstein Test a New Drug Combination to Conquer COVID-19
Albert Einstein College of Medicine

Montefiore Health System and Albert Einstein College of Medicine have begun the next stage of the Adaptive COVID-19 Treatment Trial (ACTT), to evaluate treatment options for people hospitalized with severe COVID-19 infection. The new iteration of the trial, known as ACTT 2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Newswise: New treatment extends lives of people with most common type of liver cancer
11-May-2020 11:20 AM EDT
New treatment extends lives of people with most common type of liver cancer
University of California, Los Angeles (UCLA), Health Sciences

For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer.

Released: 13-May-2020 4:05 PM EDT
Study confirms cats can become infected with and may transmit COVID-19 to other cats
University of Wisconsin-Madison

In a study published today (May 13, 2020) in the New England Journal of Medicine, scientists in the U.S. and Japan report that in the laboratory, cats can readily become infected with SARS-CoV-2, the virus that causes COVID-19, and may be able to pass the virus to other cats.

Newswise: Stroke evaluations drop by nearly 40% during COVID-19 pandemic
Released: 8-May-2020 12:30 PM EDT
Stroke evaluations drop by nearly 40% during COVID-19 pandemic
Washington University in St. Louis

A study from Washington University School of Medicine in St. Louis has found that stroke evaluations fell by nearly 40% during a period of the COVID-19 pandemic, suggesting that many stroke patients are not seeking potentially life-saving medical treatment.

Released: 28-Apr-2020 11:55 AM EDT
Experts at UTHealth successfully treat severe case of COVID-19 in 3-week-old infant
University of Texas Health Science Center at Houston

In one of the first reported cases of its kind, a 3-week-old infant in critical condition recovered from COVID-19 due to rapid recognition and treatment by physicians from McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth). The case was published April 22 in the New England Journal of Medicine.

Newswise: Study finds no overall survival benefit, but improved quality of life with talazoparib in advanced BRCA-mutated breast cancer
25-Apr-2020 12:05 AM EDT
Study finds no overall survival benefit, but improved quality of life with talazoparib in advanced BRCA-mutated breast cancer
University of Texas M. D. Anderson Cancer Center

New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes. Most patients included in the study went on to receive subsequent systemic therapies, which may have affected the survival outcome analysis. The research confirmed previous results showing talazoparib improved patient reported quality-of-life measures over available chemotherapies and had a tolerable safety profile.


Showing results

110 of 10

close
1.40502